Provided by Tiger Fintech (Singapore) Pte. Ltd.

Certara, Inc.

9.36
+0.31003.43%
Volume:1.17M
Turnover:10.48M
Market Cap:1.51B
PE:-117.00
High:9.47
Open:8.84
Low:8.64
Close:9.05
Loading ...

Company Profile

Company Name:
Certara, Inc.
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
1517
Office Location:
4 Radnor Corporate Center,Suite 350,Radnor,Pennsylvania,United States
Zip Code:
19087
Fax:
- -
Introduction:
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Directors

Name
Position
Sherilyn S. McCoy
Chairman of the Board
William F. Feehery
Chief Executive Officer and Director
Eric C. Liu
Director
Ethan Waxman
Director
James E. Cashman III
Director
Mason P. Slaine
Director
Matthew Walsh
Director
Stephen M. McLean
Director

Shareholders

Name
Position
William F. Feehery
Chief Executive Officer and Director
Judith Dickinson
Chief Human Resources Officer and Senior Vice President, Human Resources
M. Andrew Schemick
Chief Financial Officer
Richard M. Traynor
Senior Vice President and General Counsel
Craig R. Rayner
President, Integrated Drug Development
Jieun W. Choe
Chief Strategy and Marketing Officer
Justin Edge
President, Regulatory and Access
Leif E. Pedersen
President, Software
Robert Aspbury
President, Simcyp